Tumor evolution and intratumor heterogeneity in colorectal carcinoma: Insights from comparative genomic profiling of primary tumors and matched metastases

Journal of Gastrointestinal Oncology

Volumn 6, Issue 6, 2015, Pages 668-675

  Sylvester, Brooke E ^a   Vakiani, Efsevia ^b  

^a Memorial Sloan Kettering Cancer Center ^*  (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Colorectal carcinoma; Intratumor heterogeneity; Tumor evolution

Indexed keywords

CANCER CELL; CANCER GENETICS; CANCER GROWTH; CELL HETEROGENEITY; CHROMOSOME ABERRATION; COLORECTAL CARCINOMA; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; EXOME; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC SELECTION; GENETIC VARIABILITY; HUMAN; METASTASIS; MOLECULAR EVOLUTION; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; ONCOGENE; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 84995769277     PISSN: 20786891     EISSN: 2219679X     Source Type: Journal    
DOI: 10.3978/j.issn.2078-6891.2015.083     Document Type: Review

References (38)

1. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin 2014;64:104-17
2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67
3. Kennedy EP, Hamilton SR. Genetics of colorectal cancer. Semin Surg Oncol 1998;15:126-30
4. Diep CB, Kleivi K, Ribeiro FR, et al. The order of genetic events associated with colorectal cancer progression inferred from meta-analysis of copy number changes. Genes Chromosomes Cancer 2006;45:31-41
5. Kalady MF. Sessile serrated polyps: An important route to colorectal cancer. J Natl Compr Canc Netw 2013;11:1585-94
6. Korn WM, Yasutake T, Kuo WL, et al. Chromosome arm 20q gains and other genomic alterations in colorectal cancer metastatic to liver, as analyzed by comparative genomic hybridization and fluorescence in situ hybridization. Genes Chromosomes Cancer 1999;25:82-90
7. Al-Mulla F, Keith WN, Pickford IR, et al. Comparative genomic hybridization analysis of primary colorectal carcinomas and their synchronous metastases. Genes Chromosomes Cancer 1999;24:306-14
8. Aragane H, Sakakura C, Nakanishi M, et al. Chromosomal aberrations in colorectal cancers and liver metastases analyzed by comparative genomic hybridization. Int J Cancer 2001;94:623-9
9. Alcock HE, Stephenson TJ, Royds JA, et al. Analysis of colorectal tumor progression by microdissection and comparative genomic hybridization. Genes Chromosomes Cancer 2003;37:369-80
10. Jiang JK, Chen YJ, Lin CH, et al. Genetic changes and clonality relationship between primary colorectal cancers and their pulmonary metastases-an analysis by comparative genomic hybridization. Genes Chromosomes Cancer 2005;43:25-36
11. Knösel T, Schlüns K, Stein U, et al. Chromosomal alterations during lymphatic and liver metastasis formation of colorectal cancer. Neoplasia 2004;6:23-8
12. Vakiani E, Janakiraman M, Shen R, et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol 2012;30:2956-62
13. Song H, Tian Z, Qin Y, et al. Astrocyte elevated gene-1 activates MMP9 to increase invasiveness of colorectal cancer. Tumour Biol 2014;35:6679-85
14. Zeng ZS, Huang Y, Cohen AM, et al. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol 1996;14:3133-40
15. Macartney-Coxson DP, Hood KA, Shi HJ, et al. Metastatic susceptibility locus, an 8p hot-spot for tumour progression disrupted in colorectal liver metastases: 13 candidate genes examined at the DNA, mRNA and protein level. BMC Cancer 2008;8:187
16. Loo LW, Tiirikainen M, Cheng I, et al. Integrated analysis of genome-wide copy number alterations and gene expression in microsatellite stable, CpG island methylator phenotype-negative colon cancer. Genes Chromosomes Cancer 2013;52:450-66
17. Thiagalingam S, Lengauer C, Leach FS, et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 1996;13:343-6
18. Eppert K, Scherer SW, Ozcelik H, et al. MADR2 maps to 18q21 and encodes a TGFbeta-regulated MADrelated protein that is functionally mutated in colorectal carcinoma. Cell 1996;86:543-52
19. Cancer genome atlas network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-7
20. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45
21. Gibson TB, Ranganathan A, Grothey A. Randomized phase III trial results of panitumumab, a fully human antiepidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 2006;6:29-31
22. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17
23. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapyrefractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol 2010;11:753-62
24. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34
25. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8
26. Etienne-Grimaldi MC, Formento JL, Francoual M, et al. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res 2008;14:4830-5
27. Santini D, Loupakis F, Vincenzi B, et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: Implications for clinical practice. Oncologist 2008;13:1270-5
28. Oliveira C, Velho S, Moutinho C, et al. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene 2007;26:158-63
29. Albanese I, Scibetta AG, Migliavacca M, et al. Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. Biochem Biophys Res Commun 2004;325:784-91
30. Jones S, Chen WD, Parmigiani G, et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci USA 2008;105:4283-8
31. Vermaat JS, Nijman IJ, Koudijs MJ, et al. Primary colorectal cancers and their subsequent hepatic metastases are genetically different: Implications for selection of patients for targeted treatment. Clin Cancer Res 2012;18:688-99
32. Lee SY, Haq F, Kim D, et al. Comparative genomic analysis of primary and synchronous metastatic colorectal cancers. PLoS One 2014;9:e90459
33. Xie T, Cho YB, Wang K, et al. Patterns of somatic alterations between matched primary and metastatic colorectal tumors characterized by whole-genome sequencing. Genomics 2014;104:234-41
34. Brannon AR, Vakiani E, Sylvester BE, et al. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol 2014;15:454
35. Goswami RS, Patel KP, Singh RR, et al. Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. Clin Cancer Res 2015;21:2644-51
36. Diaz LA Jr, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012;486:537-40
37. Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012;486:532-6
38. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010;467:1114-7